Results from the OPEB-01/APGOT-OV4 trial highlight the potential benefits of using olaparib, pembrolizumab, and bevacizumab as a triplet maintenance therapy for patients who have responded to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results